The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: anti-HPV compositions. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
See Also:
Anti-HPV compositions is a key innovation area in genomics
Human Papillomavirus (HPV) consists of a family of small, double-stranded DNA viruses that infect the epithelium. More than 200 distinct types have been identified. High-risk or oncogenic HPV types act as carcinogens in the development of cervical cancer and other anogenital cancers. There are 7 approved HPV vaccines. The first vaccine approved by the FDA in 2006 was Gardasil developed by Merck & Co., followed by Cervarix in 2007 developed by GSK.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 300 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-HPV compositions.
Key players in anti-HPV compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to anti-HPV compositions
Source: GlobalData Patent Analytics
GSK is the leading patent filer for anti-HPV compositions. It offers drugs spanning therapeutic areas such as respiratory, oncology, immuno-inflammation, central nervous system (CNS), metabolic, cardiovascular, dermatology, bacterial infections, viral infections, including HIV, and rare diseases. GSK’s vaccine portfolio covers various diseases, including hepatitis, diphtheria, tetanus, whooping cough, rotavirus, influenza and HPV infections, measles, and bacterial meningitis, among others.
In terms of application diversity, Cue Biopharma is the top player, followed by Molecular Templates and Genexine. By means of geographic reach, Qiagen holds the top position. FDS Pharma and Aura Biosciences are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
